Heron Therapeutics (HRTX) Enterprise Value (2016 - 2025)
Heron Therapeutics (HRTX) has disclosed Enterprise Value for 14 consecutive years, with -$28.6 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value rose 51.68% year-over-year to -$28.6 million, compared with a TTM value of -$28.6 million through Dec 2025, up 51.68%, and an annual FY2025 reading of -$28.6 million, up 51.68% over the prior year.
- Enterprise Value was -$28.6 million for Q4 2025 at Heron Therapeutics, up from -$55.5 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$26.7 million in Q2 2025 and bottomed at -$257.7 million in Q2 2021.
- Average Enterprise Value over 5 years is -$84.5 million, with a median of -$58.2 million recorded in 2023.
- The sharpest move saw Enterprise Value surged 68.79% in 2023, then tumbled 61.1% in 2024.
- Year by year, Enterprise Value stood at -$71.5 million in 2021, then decreased by 18.61% to -$84.9 million in 2022, then skyrocketed by 32.79% to -$57.0 million in 2023, then decreased by 3.95% to -$59.3 million in 2024, then soared by 51.68% to -$28.6 million in 2025.
- Business Quant data shows Enterprise Value for HRTX at -$28.6 million in Q4 2025, -$55.5 million in Q3 2025, and -$26.7 million in Q2 2025.